Net Loss per Share

6 Months Ended

Jun. 30, 2012

8. Net Loss per Share

Basic and diluted net loss per share is presented in conformity with ASC Topic 260, “Earnings per Share,” for all periods presented. In accordance with ASC Topic 260, basic and diluted net loss per common share was determined by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding during the period. Diluted weighted-average shares are the same as basic weighted-average shares since the inclusion of issuable shares pursuant to the exercise of stock options and warrants, and the conversion of preferred stock would have been antidilutive.

The following table sets forth the potentially dilutive effect of all outstanding equity instruments which were not included in the computation of diluted earnings per share because they would be antidilutive.

	June 30, 2012	June 30, 2011

Common Shares outstanding	158,516,071	158,516,071
Potentially dilutive common shares issuable upon:
Exercise of warrants	988,741	9,290,248
Exercise of Callisto stock options	5,756,237	7,435,371
Conversion of Series A Convertible Preferred Stock	222,222	222,222

Total fully diluted	165,483,271	175,463,912

- Definition

The entire disclosure for earnings per share.

+ References+ Details

CALLISTO PHARMACEUTICALS INC 10-Q/A